



NateraCore

Support every step of the way



We hear your concerns...

Time with my patients is precious and limited

I need an easier way

I'm a clinician, not a billing expert

This needs to fit into my practice workflow

I don't have time on my day as it is

I spend too much time talking about insurance

Guidelines and coverage policies are complex and rapidly changing

A high-angle photograph of a woman with curly hair, wearing light blue scrubs, standing on a grey tiled floor. She is holding a tablet computer and looking at the screen. The floor has shadows cast across it, suggesting bright overhead lighting. In the center of the image, there is a large graphic consisting of three concentric circles: a central green circle, a middle light blue circle, and an outer white circle. The text 'Natera Core' is centered within the green circle.

Natera
Core

Your integrated support resource



**Natera
Core**

Supporting our comprehensive menu of genetic tests for Women's Health

Horizon™
Advanced carrier screening

Vistara™
Single-gene NIPT

Panorama™
Next-generation NIPT

Anora®
Miscarriage test (POC)

Spectrum™
Preimplantation genetics

Empower™
Hereditary cancer test

Your integrated support resource

Services for providers and patients at every step



Education

Patient-friendly materials and information sessions, covering basic genetics to specific tests



Access

Programs and price transparency – rooted in our commitment to provide affordable testing for all who can benefit



Ordering

Flexible options based around your needs, including intuitive remote ordering and EMR solutions



Results

Clear, actionable reports, served with time-saving tools and access to expert guidance



Next Steps

Value-add services that go beyond the test to address what's next

Supporting both in-office and remote workflows



Education

Patient-friendly materials and information sessions, covering basic genetics to specific tests

Patient brochures, videos, and online content



Brochures



Videos



Online content

Genetic information sessions and family history intake



Pre-test genetic information sessions




Pre-test family history and education with NEVA

Texting program



Office posters




Patient cards



Access

Programs and price transparency —
rooted in our commitment to
provide affordable testing for all
who can benefit

Broad in-network coverage



View a list of [in-network plans](#)

Personalized cost estimates



Pre-test cost
estimates




Price Transparency
Program (PTP)

Financial access programs



Compassionate
Care Program



Self-pay
cash option



Interest-free
payment plans



Ordering

Flexible options based around your needs, including intuitive remote ordering


A range of ordering options

Epic

Cerner

athenahealth

NateraSync EMR Solutions



Online via NateraConnect

Flexible phlebotomy options



Patient Service Centers (PSC)



Nationwide mobile phlebotomy service

End-to-end remote testing



Online education and cost estimates



Virtual Testing (Simple Ordering)




Post-test Sessions scheduled by phone or online




Results

Clear, actionable reports,
served with time-saving
tools and a side of
expert guidance

Online results management



Results tracking



Patient results-release settings

Flexible results delivery options



Positive results delivery via
Genetic Information Session



E-Results Sync: Results
delivery to the EMR

Patient Call-Out Program (PCOP) with NEVA



Interactive results
delivery with NEVA



Proactive GIS scheduling for
positive results






Next Steps

Value-add services that go beyond the test to address what's next

Post-test genetic info sessions and provider consultations



Schedule by:

-  Calling Natera Customer Care
-  Visiting the online patient portal
-  Texting SESSION to 484848 (patients only)

Family testing program



Empower testing for first-degree relatives of patients with a positive result is available at no additional charge.

 Visit natera.com/empower for more details.

Spectrum Advantage Program



Empower and Horizon patients can access Spectrum preimplantation genetic testing at discounted rates



Education





Education

Patient-friendly materials and information sessions, covering basic genetics to specific tests

Educational resources for patients



Brochures



Videos



Online content

Genetic information sessions and family history intake



Pre-test genetic information sessions




Streamlined family history collection with NEVA

Texting program




Office posters




Patient cards

Texting program

Convenient access to education and other key services




Office posters




Patient cards

On Demand Education and Counseling

Natera provides genetic education throughout the testing process



**NEVA, Natera's
Educational Virtual
Assistant**



Educational videos



**Genetic information
sessions**

Pre-test genetic information sessions

Pre-test genetic information sessions



Schedule by:



Calling Natera Customer Care at
(844) 778-4700



Visiting the online patient portal
my.natera.com/services/genetic_information



Texting **SESSION** to **484848**

Hereditary Cancer Risk Assessment Tools

Efficiently identify patients meeting criteria for testing

natera | Empower™
Hereditary cancer test

TODAY'S DATE: _____ NAME: _____ AGE: _____ DATE OF BIRTH: _____

Family History Questionnaire

Please answer the following questions to the best of your knowledge to help your care team understand cancer patterns in your family. For more information, text EMPOWER to 484848.

Select Yes/No and enter information in the accompanying boxes of the same row. Family members include parents, siblings, children, uncles, aunts, first cousins, grandparents, grandchildren, nieces, nephews, or half-siblings.

Please complete the following for you and your family members:	Age at diagnosis		Enter family member and age at diagnosis		
	You	Siblings/Children	Mother's side	Father's side	
Example: Breast cancer	<input checked="" type="checkbox"/> Y <input type="checkbox"/> N	Age 46	Sister, 25	Aunt, #1 65 Aunt, #2 48	Grandma, #1
1. Breast cancer < age 50	<input type="checkbox"/> Y <input type="checkbox"/> N				
2. Either colon cancer or uterine cancer < age 50	<input type="checkbox"/> Y <input type="checkbox"/> N				
3. Triple negative breast cancer < age 60	<input type="checkbox"/> Y <input type="checkbox"/> N				
4. Two or more breast cancers in the same person (first diagnosis < age 50)	<input type="checkbox"/> Y <input type="checkbox"/> N				
5. Two or more colon and/or uterine cancers in the same person	<input type="checkbox"/> Y <input type="checkbox"/> N				
6. Two family members with breast, colon or uterine cancer (one < age 50)	<input type="checkbox"/> Y <input type="checkbox"/> N				
7. Three or more family members from the same side with breast cancer	<input type="checkbox"/> Y <input type="checkbox"/> N				
8. Three or more family members with colon and/or uterine cancer	<input type="checkbox"/> Y <input type="checkbox"/> N				
9. Ovarian cancer	<input type="checkbox"/> Y <input type="checkbox"/> N				
Pancreatic cancer	<input type="checkbox"/> Y <input type="checkbox"/> N				
Male breast cancer	<input type="checkbox"/> Y <input type="checkbox"/> N				
10 or more precancerous colorectal polyps	<input type="checkbox"/> Y <input type="checkbox"/> N				
10. Ashkenazi Jewish AND breast cancer or prostate cancer	<input type="checkbox"/> Y <input type="checkbox"/> N				
11. You or a close family member has a known gene mutation. Please list _____	<input type="checkbox"/> Y <input type="checkbox"/> N				
12. Other cancers not listed above _____	<input type="checkbox"/> Y <input type="checkbox"/> N				
13. Other concern about your cancer risk _____	<input type="checkbox"/> Y <input type="checkbox"/> N	Please explain:			

If you have never been diagnosed with breast cancer, please complete the following questions.

1. Height (ft/in) _____ 2. Weight (lbs) _____ 3. Have you had children? Y N How old were you when you had your first child? _____

4. Approximate age at first menstrual period? _____ 5. Have you gone through menopause? Y N Ongoing If yes, at approximately what age? _____

6. Are you of Ashkenazi Jewish descent? Y N I don't know

7. Have you ever used hormone replacement therapy? Y N Ongoing If yes, when? Start date _____ End date _____
If yes, what type? Estrogen Progesterone Combined I don't know

8. How many sisters do you have? _____ Daughters? _____ Maternal aunts? _____ Paternal aunts? _____ Maternal half-sisters? _____ Paternal half-sisters? _____

9. Have you ever had a breast biopsy? Y N If yes, what was the result? Hyperplasia Atypical hyperplasia LCIS I don't know

Signatures

Patient Name _____ Patient Signature _____ Date _____

Provider Name _____ Provider Signature _____ Date _____

For Office Use Only

A "Yes" answer to any of questions 1-11 indicates your patient may meet criteria for hereditary cancer testing.

Patient offered hereditary cancer genetic testing (check all that apply)

Yes No Patient accepted Patient declined

MLB-1998 © 2021 Natera, Inc. All Rights Reserved. EMP_OB_Family History Questionnaire_20210712_NAT_48202121 201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1.855.249.9090

Please check all that apply

natera | Empower™
Hereditary cancer test


Have you or a close relative (parents, siblings, children, uncles, aunts, first cousins, grandparents, grandchildren, nieces, nephews, or half-siblings) had any of the following:

- 1 breast, colon, or uterine cancer diagnosed under age 50
- Ovarian cancer, pancreatic cancer, or male breast cancer diagnosed at any age
- 3 breast cancers on the same side of family diagnosed at any age
- Ashkenazi Jewish ancestry with breast cancer or prostate cancer diagnosed at any age
- 3 or more colon and/or uterine cancers on the same side of family diagnosed at any age

Hereditary cancer testing helps you understand if you have increased risk for developing cancer. I want to discuss this with my provider: Y N

Patient name: _____

Provider you are seeing today: _____


 For more information, text **EMPOWER** to 484848

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2020 Natera, Inc. All Rights Reserved.

NEVA for Risk Assessment

NEVA makes it easier to collect family cancer history

Hi, I'm NEVA, and I have a few questions about your family history of cancer




- AI-enabled family history collection based on the latest NCCN guidelines
- Trained by Natera's expert genetic counselors and has provided interactive education to thousands of patients
- NEVA is EMR-connected to simplify the education and risk assessment workflow
- NEVA is available to patients 24/7/365
- Rated as friendly, knowledgeable, and helpful for your patients

NEVA EMR Sync automates the pre-test workflow

Automate invites through integration with the EMR-based patient schedule


1

An invite is automatically sent 7 days prior to appointment




2

Once a patient completes NEVA, the summary is sent to the patient record in the EMR



3

Clinician reviews NEVA summary and orders Empower during appointment



Invite Your Patients to Chat with NEVA

Send invitations from your NateraConnect ordering platform in three ways

1

Invite individual patients
from Connect

New Patient ×

First Name

Last Name

Date Of Birth

Email

Appointment Date

2

Upload patient list in
Connect for batch invites

Appt date	First Name	Last Name	Date of Birth	Email address
12/1/2020	Jane	Doe	1/1/1990	jane@
12/1/2020	Jeremy	Smith	5/20/1975	Jeremy@
12/1/2020	Jamie	Jones	6/3/1982	Jamie@

3

Generate clinic-specific URL,
shareable via email/text or
within QR code

Hi, I'm NEVA, and I have a few questions about your family history of cancer.

PLEASE SCAN
to complete your family history questionnaire.

Or visit:
connect.natera.com/Dr_Eric_Chen


natera | Empower family cancer test

Patient completes education and risk assessment in NEVA

NEVA guides patients through family cancer history questions


1

An email and/or text message is sent to the patient to complete NEVA




2

Patients are guided through questions about their personal and family history of cancer.



3

You are ready to discuss testing with appropriate patients at their appointment.



Risk Assessment Results

natera | Empower™
Hereditary cancer test

About this test: Empower is used to identify risk from common hereditary cancer genes. This information may help individuals learn if they have an elevated risk for developing certain cancers over their lifetime.

⚠️ This patient appears to meet medical guidelines (NCCN or USPSTF) for hereditary cancer testing. See 'Risk Reason' below for details.


PATIENT DETAILS		
Patient Name	Date of Birth	Gender
Mary Doe	11/23/1970	Female
Phone	Email	Ethnicity
888-888-8888	marydoe@gmail.com	Caucasian
Risk Assessment Level	Risk Reason	Risk Assessment Available
Elevated	Family history	01/12/2020
Patient Interested in Test?	Appointment Date	
Yes	01/01/2021	

PATIENT HISTORY OF CANCER	
Cancer Type	Age at diagnosis
Breast	39

Access and Complete Prefilled Test Orders

Submit orders in NateraConnect

Select appropriate test panel



Empower™
Hereditary cancer test

Panel options

BRCA1 & BRCA2

Add 17 genes for GYN, Guidelines-based (total 19)

Add 38 genes for Multi-Cancer (total 40)

Add 51 genes for Multi-Cancer, Expanded (total 53)

Select ICD-10 Diagnosis Codes

Z85.3 - Personal history of malignant neoplasm of breast

Z85.43 - Personal history of malignant neoplasm of ovary

Z80.0 - Family history of malignant neoplasm of digestive organs [pancreas]

Prefilled family history details

Patient Personal History of Cancer

No

Patient Family History of Cancer

Yes

Family Member #1

Relationship: Mother

Maternal or Paternal: Maternal

Cancer Site(s): Breast

Age at Dx: 44

[Add another family member](#)

This order is for Family Testing Program

Saliva kit and mobile phlebotomy options

Enter Kit Information

I want Natera to ship a blood kit to this patient

I want Natera to ship a saliva kit to this patient

I'll print the completed order form and attach it to patient's sample OR enter the kit ID at a later time

[Return to add Kit ID](#)



Access






Access

Programs and price transparency —
rooted in our commitment to
provide affordable testing for all
who can benefit

Broad in-network coverage



View a list of [in-network plans](#)

Personalized cost estimates



Pre-test cost
estimates




Price Transparency
Program (PTP)

Financial access programs



Compassionate
Care Program




Self-pay
cash option



Interest-free
payment plans

High-Quality Testing, Made Affordable

We work from all angles to give patients access to testing, and help providers stay focused on care.



Broad in-network coverage



Personalized cost estimates




Financial access programs

In-Network Provider with Most Insurance Plans

Natera is proud to accept most national and regional healthcare plans.



View Natera's [in-network plans](#)



Pre-test cost estimates

Obtain via:



Email: estimate@natera.com



Text: **650.210.7046**



Price Transparency Program (PTP)

Personalized cost estimates and \$249 self-pay cash option

1



Your medical provider orders a test. We start processing your sample.



2



We generate an insurance estimate.



3



If we estimate your cost to exceed \$249,² we'll contact you via text or email and you choose how you pay: insurance or cash.



4



If you choose insurance, we'll send you a bill once your health plan confirms exactly how much you owe.

If you choose insurance

If you've not met your deductible, what you pay will go towards that amount, after which insurance begins to contribute to your care.

If your insurance plan denies the claim, you will be eligible for our discounted cash price.

¹ Estimates are based on previously processed claims from 2017-2018.
² \$349 if ordering microdeletions or Horizon extended panels.

Price Transparency Program (PTP)

Personalized cost estimates and self-pay cash option

1



Your medical provider orders a test. We start processing your sample.



2



We generate an insurance estimate.



3



If we estimate your cost to exceed self-pay cash option, we'll contact you via text or email and you choose how you pay: insurance or cash.



4



If you choose insurance, we'll send you a bill once your health plan confirms exactly how much you owe.


If you choose insurance

If you've not met your deductible, what you pay will go towards that amount, after which insurance begins to contribute to your care.


If your insurance plan denies the claim, you will be eligible for our discounted cash price.

Price Transparency Program (PTP)

Non-covered Service




Out of Network



Price Transparency Program (PTP)

Example PTP Patient Messages when Pre-Test Counseling by 3rd Party GC is Required



Compassionate Care Program

Testing from \$0 to \$149 for patients experiencing financial hardship

Annual Household Income Equal to or Less Than

Total Household Size (Including unborn child)	1	\$49,960	\$37,470	\$24,980
	2	\$67,740	\$50,730	\$33,820
	3	\$85,320	\$63,990	\$42,660
	4	\$103,000	\$77,250	\$51,500
	5	\$120,680	\$90,510	\$60,340
	6	\$138,360	\$103,770	\$69,180
	7	\$156,040	\$117,030	\$78,020
	8	\$173,720	\$130,290	\$86,860
		\$149/test	\$99/test	\$0/test

Apply by:



Visiting the online patient portal



Submitting a paper application

Connect Cost Calculator

Real-time cost estimates via online portal



PATIENT COST ESTIMATE

Estimated out-of-pocket cost paying with insurance

\$150.00

This estimate is based on your patient's plan deductible and co-insurance as of November 24

Deductible: **\$730.00**

Co-insurance: **\$8.72**


This patient's 'Deductible' is the dollar amount they must pay before their plan begins to contribute to the cost of their care. Most patients who receive reproductive care do meet their deductible, so what they pay for their test will help meet that amount.

Self Pay Cash Price

\$249.00

When the patient chooses the self-pay cash price, we will not bill their insurance and they not owe anything additional.

But remember, this means what they pay will not be counted towards their deductible.



- Pre-test cost estimates can be generated by Cost Calculator in NateraConnect
- Both out-of-pocket cost with insurance and self pay cash price are provided
- Available for Panorama, Horizon, and Empower



Ordering





Ordering

Flexible options based around your needs, including intuitive remote ordering


A range of ordering options

Epic

Cerner

athenahealth

NateraSync EMR Solutions



Online via NateraConnect

Flexible phlebotomy options



Patient Service Centers (PSC)



Nationwide mobile phlebotomy service

End-to-end remote testing



Online education and cost estimates




Virtual Testing (Simple Ordering)



Post-test Sessions scheduled by phone or online

Flexible ordering options to suit your needs


Ranging from paper reqs to entirely digital solutions



Paper requisitions



NateraSync EMR Solutions



Online via NateraConnect

Online ordering

Streamlined step-by-step guided workflow

Physician

Initiates order via NateraConnect

Provides patient payment information

Patient

Receives text/email to schedule blood draw [optional]

Physician

Receives results

Gene	Frequency	Prevalence	Protein Product	Associated Cancer
BRCA1	1:300	1:400	BRCA1	Breast, Ovarian
BRCA2	1:250	1:300	BRCA2	Breast, Prostate, Pancreatic
PALB2	1:5,000	1:10,000	PALB2	Breast

- ✓ Enter basic patient information
- ✓ Select desired test panel
- ✓ Use in-office kit or invite patient for remote blood draw options


- ✓ Enter patient insurance information
- ✓ Sign order

- ✓ Schedules blood draw via patient portal

- ✓ Stay informed on Order status

Virtual testing (aka Simple Ordering)

Streamlined step-by-step guided workflow



- ✔ Select test
- ✔ Use sample kit (if available in office)
- ✔ Invite patient via email or text
- ✔ Learn genetic risks
- ✔ Know testing process
- ✔ Watch on phone/mobile device
- ✔ Provide insurance
- ✔ Get cost estimate
- ✔ Learn about compassionate care
- ✔ Documented patient approval or denial
- ✔ 5–7 days for Panorama
- ✔ ~2 weeks for Horizon

Online Ordering and Virtual Testing Workflows

Which workflow is right for you?

	Virtual Testing (Simple Ordering)	Online Ordering
Provider initiates online order via NateraConnect	✓	✓
Patient receives email/text to complete order	✓	✗
Patient watches test-education video	✓	✗
Patient enters insurance information	✓	✓ (Provider)
Patient receives pre-test cost estimate	✓	✗
INPUT submits partner information (for PAE, joint reports)	✓	✗
Patient receives flexible phlebotomy options	✓	✓

Potentially appropriate use cases

- | | |
|---|--|
| <ul style="list-style-type: none"> Fully virtual/remote testing | <ul style="list-style-type: none"> Online ordering |
| <ul style="list-style-type: none"> Minimal provider workload desired | <ul style="list-style-type: none"> Control over workflow desired |
| <ul style="list-style-type: none"> Compliant patient population | <ul style="list-style-type: none"> Less-compliant patient population |
| <ul style="list-style-type: none"> Integrated pre-test education and cost estimate desired | <ul style="list-style-type: none"> Existing patient-education process |

NateraSync EMR Solutions

Modular services configurable to your EMR system and business requirements



Epic EMR Solutions

Streamlined ordering and results solution developed by Epic



e-Results Sync

Patient lab results delivered directly to your EMR and can be routed to patient record



Total EMR Sync

Full bi-directional data and workflow interoperability with HL7 interface development

Secure

Direct HIPAA compliant data exchange



Flexible

>100 EMR vendors supported



Proven

>1,500 accounts successfully integrated



Epic Orders and Results Anywhere Network

Order tests and receive results directly in your Epic EMR with new Epic solution

How it Works

- Epic's *Order and Results Anywhere* network allows Epic customers to easily enable ordering and results delivery in the EMR
- Delivers the benefits of a traditional HL7 bi-directional integration without the long timelines and costly implementation.

Get Started

- Connect to the Orders and Results Anywhere network with less than 24 hours of total work time.
- Epic Sherlock Checklist available to understand implementation process
- Natera EMR Support Team available to assist with implementation

Available with

Panorama™
Next-generation NIPT

Horizon™
Advanced carrier screening

Empower™
Hereditary cancer test

Prospera™
Transplant assessment

Spectrum™
Preimplantation genetics

Renasight™
Kidney gene panel

Anora™
Miscarriage test (POC)

Signatera™
Residual disease test (MRD)

Altera™
Tumor genomic profile

Epic Orders and Results Anywhere Network

Ordering

The screenshot shows the Epic Ordering interface for a patient named Chelsea Johnson. A modal window for "Horizon 14 (Pan-Ethnic Standard)" is open, displaying the following information:

- Status:** Normal (Selected), Standing, Future
- Add-on:** No add-on specimen found
- Priority:** Routine
- Specimen Src:** (Empty)
- Comments:** Includes a consent form with questions like "Is the patient pregnant?" and "I authorize Natera to share patient's Horizon test results with partner and their medical provider."
- Class:** Clinic Collect (Selected), Lab Collect, Print
- CC Results:** Recipient, Modifier, Add PCP, Add My List, Build My Lists, Clear All

Buttons for "Accept" and "Cancel" are visible at the bottom of the modal.

Results

The screenshot shows the Epic Results interface. A list of results is displayed, and a detailed view for "Horizon 14 (Pan-Ethnic Standard)" is open, showing the following information:

- Patient:** Chelsea Johnson, Female, 29 y.o., 10/28/1991, MRN: 32895, Phone: 608-645-9834 (H) ...
- PCP:** Marty Seeger, M.D., Primary Cvg: Epic Us Healthcar...
- Order:** 1559691
- Status:** Final result
- Visible to patient:** No (not released)
- Component:** 16:17
- Interpretation:** NEGATIVE FOR 14 OUT OF 14 DISEASES
- Resulting:** WSIL
- Agency:** (Empty)
- Specimen Collected:** 05/13/21 16:17, Last Resulted: 05/13/21 16:17

Buttons for "Lab Flowsheet", "Order Details", "View Encounter", "Lab and Collection Details", "Routing", and "Result History" are visible at the bottom of the detailed view.

Mobile phlebotomy services

- Available in all 50 states
- No cost to patient
- Patient can schedule by:



Visiting the online patient portal



Texting **DRAW** to **484848**



Note: Patients are required to have kit and req for appointment (can be shipped to patient).

Not for reproduction or further distribution.

NateraConnect

Accessing online ordering




Benefits:

- Initiation of test orders
- Step-by-step guided workflow with no missing information
- Paperless process
- Real-time order status



Offers fully virtual testing when combined with:

- Mobile phlebotomy
- Patient pre-test education
- Pre-test cost estimate



NateraConnect

Online provider portal for integrated testing management

- Track order status, view results, and correct missing information
- Order kits, requisitions, and patient brochures.
- Locate blood-draw resources.
- Manage preferences for releasing results to patients.



NateraConnect main dashboard

NateraConnect — use overview

Locating patient results



Easy access to check on your patient's results

The screenshot displays the NateraConnect web application interface on a laptop. The interface includes a sidebar with navigation options, a search bar, and a 'Case Results' table. A blue callout bubble points to the 'View Test Results' option in the sidebar.

Case Results

Download Selected Results Clear Search

All Test Types All Statuses All Result Types All Providers

Results 11 to 20 of 2452 (filtered from 3054 total)

Case ID	Patient / Partner	Egg Donor ID	3rd Party ID	Test	Status	Result	Provider	Rec
<input type="checkbox"/> 1283414	PT-147			Panorama	Closed			06/
<input type="checkbox"/> 1283398	PT-146			Panorama	Closed			06/
<input type="checkbox"/> 1262795	1262795, 1262795			Panorama	Closed			05/
<input type="checkbox"/> 1262317	PT-150			Panorama	Processing			05/
<input type="checkbox"/> 1262311	PT-149			Panorama	Processing			05/
<input type="checkbox"/> 1262306	PT-148			Panorama	Processing			05/
<input type="checkbox"/> 1262303	PT-147			Panorama	Processing			05/
<input type="checkbox"/> 1262298	PT-146			Panorama	Processing			05/
<input type="checkbox"/> 1255828	Devereaux, Kelly			Horizon	Processing			05/
<input type="checkbox"/> 1255783	Loring, Justin			Horizon	Closed			05/

Page 2 of 246

NateraConnect — use overview

Viewing and correcting missing information



Case ID: 3178233 | Provider: Danni Connolly Kelly

Sample Received: 03/05/20

Missing information: missing information or Contact Customer Care at 1-844-778-4700.

Provider can click here to submit information back to Natera

PHI is masked out, but patient name will be listed here

Missing Information
We are missing information from the test order which may be resolved by contacting the missing information or by contacting Customer Care at 1-844-778-4700 for international clinics. For more information, visit [natera.com](#) or at support@natera.com.

[Correct Missing Information](#)

Test Details

Status	Missing Info
Case ID	3178233
Third Party ID	CONNECT
Patient	DOB: 04/23
Test Type	Panorama
Provider	Danni Connolly
Clinic	Beta OB/G


Questions about this case?

Samples


Subject	Barcode	Sample Type	Date Sample Received	Date Sample
Patient	9471827-1-2-EM	Blood	Mar 5, 2020	Mar 4, 20
	9471827-2-2-EM	Blood	Mar 5, 2020	Mar 4, 20
Partner				

NateraConnect — use overview

Ordering test kits



Visit NateraConnect to order kits and have them sent directly to your clinic.




NateraConnect — use overview

Ordering requisition forms



Visit NateraConnect to order two- and three-ply custom requisition forms.




NateraConnect — use overview

Ordering patient brochures



Visit NateraConnect
to order patient brochures
for your office.




NateraConnect — use overview

Locating blood-draw resources




Visit NateraConnect to locate the nearest Patient Service Center (patient blood-draw location).



Flexible phlebotomy options

Patient access via my.natera.com




A range of patient-selected draw locations

Including Patient Service Centers (PSC) or mobile blood draw (at-work or at-home)



Patients can also text **DRAW** to **484848** to access blood-draw options.





Results







Results

Clear, actionable reports,
served with time-saving
tools and a side of
expert guidance

Online results management



Results tracking



Patient results-release settings

Flexible results delivery options



Positive results delivery via
Genetic Information Session



E-Results Sync: Results
delivery to the EMR

Patient Call-Out Program (PCOP) with NEVA



Interactive results
delivery with NEVA



Proactive call out to
clinicians for positive results

e-Results Sync

Receive patient lab results directly in your EMR

How it Works

- Patient lab results are sent directly to your EMR inbox through DIRECT messaging, available in nearly every EMR.
- Once received, simply attach the PDF result to the patient record, eliminating the need to scan paper test results.

Get Started

- Once your DIRECT EMR address is confirmed, Natera will enable results delivery in less than a day.
- If you do not have a DIRECT address, one can be created by your hospital's IT team.

Compatible Tests

Panorama™
Next-generation NIPT

Horizon™
Advanced carrier screening

Anora™
Miscarriage test (POC)

Spectrum™
Preimplantation genetics

Empower™
Hereditary cancer test

Prospera™
Transplant assessment

Online results management

Results tracking (checking sample status and case details)



PT-150
Case ID: 1262317

Sample Received 05/15/17 Processing This case result has not yet been delivered. Results Delivered to Provider

Status Details
Processing
This case result has not yet been delivered.
If you have any concerns, please contact Customer Care at 1-844-778-4700 or send us a message through the message center.

Test Details

Status	Processing
Case ID	1262317
Patient	PT-150 DOB: 02/02/1982
Test Type	Panorama
Clinic	Natera, Inc.

Questions about this case? Call 1-844-778-4700

Samples

Received Samples

Subject	Barcode	Sample Type	Date Sample Received	Date Sample C
Patient	3569401.1-2-BM	Blood	May 15, 2017	May 15, 2017
	3569401.2-2-BM	Blood	May 15, 2017	May 15, 2017
Partner				


Samples are displayed here

Online results management

Selecting patient results-release timing



NateraConnect enables you to select when results are released to patients. Results will automatically release to patients after the specified number of days. Release timing can be customized for negative vs. positive results, and a range of between 1 – 10* days can be set.




*Release timing can be set for between 1 - 30 days for Empower.

Interactive results delivery via NEVA


Natera's Educational Virtual Assistant

How would you like to review your Horizon results?



NEVA


NEVA makes genetic information sessions more accessible



- Rapid, convenient patient access to results and counseling for patients, 24 x 7 x 365
- Complements genetic information sessions for patients
- Accurate information written by genetic counselors
- AI-enabled technology
- Patient-rated as friendly, knowledgeable, and helpful

NEVA


NEVA uses an interactive interface to communicate with patients



Patient Call-Out Program (PCOP) with NEVA


Provider

Receives patient results¹




Patient

Receives email/text to log onto Patient Portal and NEVA greets patient




Completes NEVA or schedules genetic information session²



Provider

Receives email/fax documenting NEVA session completed





- ✓ NEVA session transcript can be downloaded by patient and provider
- ✓ Patient receives Horizon results report

1. ~1 business day between when provider receives patient's results and patient receives email/text to log onto Patient Portal


2. If patient is positive and does not complete NEVA interaction, Natera customer care will contact patient

NEVA supports scalable and convenient post-test counseling



>12,000
Carrier Screening
Sessions Completed
by the NEVA

Empower: Post-test Workflow



NIPT Gender Sender

Simplifying fetal-sex reporting for patients and providers

Physician → NateraConnect


Release report to patient as usual



- ✓ Release manually or NateraConnect can release automatically
- ✓ You're done!


Patient → My Natera portal

Option to view report with or without fetal sex



- ✓ Chooses not to see fetal sex
- ✓ Reviews results before sending fetal sex information
- ✓ Always has option to see fetal sex if desired

Option to send fetal sex to friends and family



Friend → Email

3rd party receives fetal sex results



- ✓ Surprise reveal can be planned

Patient-friendly reports



Panorama NIPT

Low-risk, Singleton report

FINAL RESULTS SUMMARY

Result

LOW RISK



Fetal Sex

Male



Fetal Fraction

8.3%



Notes by the clinical reviewer, if any, will be shown here.

RESULT DETAILS: ANEUPLOIDIES

Condition tested ¹	Result	Risk Before Test ²	Risk After Test ³
Trisomy 21	Low Risk	1/152	<1/10,000
Trisomy 18	Low Risk	1/354	<1/10,000
Trisomy 13	Low Risk	1/1,116	<1/10,000
Monosomy X	Low Risk	1/255	<1/10,000
Triploidy	Low Risk		

RESULT DETAILS: MICRODELETIONS

Condition tested ¹	Result	Risk Before Test ²	Risk After Test ⁴
22q11.2 deletion syndrome	Low Risk	1/2,000	1/9,000

Patient-friendly reports



Panorama NIPT

High-risk Trisomy 21,
Singleton report

FINAL RESULTS SUMMARY

Result

HIGH RISK for Trisomy 21



Fetal Sex

Male



Fetal Fraction

8.3%



This is a screening test only. Genetic counseling and diagnostic testing should be offered to further evaluate these findings.

Panorama analyzes DNA from the placenta. In some cases placental DNA can differ from that of the fetus; therefore, no irreversible decisions should be made based upon results of this screening test alone.

RESULT DETAILS: ANEUPLOIDIES

Condition tested ¹	Result	Risk Before Test ²	Risk After Test ³
Trisomy 21	High Risk	1/152	9/10
Trisomy 18	Low Risk	1/354	<1/10,000
Trisomy 13	Low Risk	1/1,116	<1/10,000
Monosomy X	Low Risk	1/255	<1/10,000
Triploidy	Low Risk		

Patient-friendly reports



Horizon

Negative report

Patient Information

Patient Name: Jane Doe
Date of Birth: 02/02/1975
Gender: Female
Ethnicity: Hispanic
Patient ID: P99457
Medical Record #: M84555
Collection Kit: 254233-2-N
Accession ID: 40192731
Case File ID: 123456

Test Information

Ordering Physician: Dr. Goodbirth, M.D.
(G123456)
Clinic Information: Natera, Inc.
Phone: 650 555-1212
Report Date: 02/01/2013
Sample Collected: 01/31/2013
Sample Received: 02/01/2013
Sample Type: Blood



CARRIER SCREENING REPORT

ABOUT THIS SCREEN: Horizon™ is a carrier screen for specific autosomal recessive and X-linked diseases. This information can help patients learn their risk of having a child with specific genetic conditions.

ORDER SELECTED: The Horizon 27 panel was ordered for this patient.

FINAL RESULTS SUMMARY:



NEGATIVE FOR 27 OUT OF 27 DISEASES

No pathogenic variants were detected in the genes that were screened. The patient's remaining carrier risk after negative screening results is listed for each disease/gene on the Horizon website at <http://www.natera.com/hrzn27s>. Please see the following pages of this report for a comprehensive list of all conditions included on this individual's screen.

Carrier screening is not diagnostic and may not detect all possible pathogenic variants in a given gene.

Patient-friendly reports



Horizon Joint report

UXMSNGA
HUGNEYD
Date of Birth: 01/01/1990
Gender: Female
Ethnicity: African American
Collection Kit: 925301715-2-C
Case File ID: 3899350
Report Date: 03/15/2021
Ordering Physician:

BJYSMGY
OAZCPHS
Date of Birth: 01/01/1990
Gender: Male
Ethnicity: African American
Collection Kit: 925309034-2-C
Case File ID: 3899351
Report Date: 03/15/2021
Ordering Physician:



Horizon™
Advanced carrier screening

FINAL RESULTS SUMMARY:

Risk Details	UXMSNGA HUGNEYD	BJYSMGY OAZCPHS	Reproductive Risk
Panel Information	Horizon 274 Carrier Screening Panel	Horizon 274 Carrier Screening Panel	
Spinal Muscular Atrophy Gene: <i>SMN1</i>	CARRIER SMN1: 1 copy	CARRIER SMN1: 1 copy	1 in 4

Carrier screening is not diagnostic and may not detect all possible pathogenic variants in a given gene.

RECOMMENDATIONS

Individuals who would like to review their Horizon report with a Natera Laboratory Genetic Counselor may schedule a telephone genetic information session by calling 650-249-9090 or visiting naterasession.com. Clinicians with questions may contact Natera at 650-249-9090, 855-866-6478 (toll free) or email support@natera.com. Individuals with positive results may wish to discuss these results with family members to allow them the option to be screened. Comprehensive genetic counseling to discuss the implications of these test results and possible associated reproductive risk is recommended.

Patient-friendly reports



Horizon

Positive report

Patient Information

Patient Name: John Doe
Date of Birth: 02/02/1975
Gender: Male
Ethnicity: Hispanic
Patient ID: P99457
Medical Record #: M84555
Collection Kit: 254233-2-N
Accession ID: 40192731
Case File ID: 123456

Test Information

Ordering Physician: Dr. Goodbirth, M.D.
(G123456)
Clinic Information: Natera, Inc.
Phone: 650 555-1212
Report Date: 02/01/2013
Sample Collected: 01/31/2013
Sample Received: 02/01/2013
Sample Type: Blood



CARRIER SCREENING REPORT

ABOUT THIS SCREEN: Horizon™ is a carrier screen for specific autosomal recessive and X-linked diseases. This information can help patients learn their risk of having a child with specific genetic conditions.

ORDER SELECTED: Cystic Fibrosis was ordered for this patient.

FINAL RESULTS SUMMARY:



CARRIER for Cystic Fibrosis

Positive for the pathogenic variant [name of mutation] in the CFTR gene. If the patient's partner is a carrier for Cystic Fibrosis, their chance to have a child with this condition is 1 in 4 (25%).

Carrier screening is not diagnostic and may not detect all possible pathogenic variants in a given gene.

Patient-friendly reports



Empower Negative report

FINAL RESULTS SUMMARY



Negative

No known pathogenic or likely pathogenic variants were detected.

Interpretation

No known or potential disease-causing pathogenic variants or variants of uncertain significance were detected by the methods described in the Methodology & Limitations section below.

Genes analyzed on this panel

APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM, HOXB13, KIT, MEN1, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PDGFRA, PMS2, PTEN, RAD50, RAD51C, RAD51D, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, TSC1, TSC2, VHL, MSH3, POLE, RPS20, POLD1, NTHL1, AXIN2, BAP1, CTNNA1, GALNT12, GREM1, RNF43

Recommendations

Clinical correlation and genetic counseling are recommended for this individual to discuss associated cancer risks as well as cancer screening and prevention/risk reduction options. Test results should be interpreted in the context of the patient's clinical presentation and family history. Medical management should be based on the patient's clinical risk factors such as family history, lifestyle and age.

Individuals who would like to review their Empower test report with a Natera Laboratory Genetic Counselor may schedule a telephone genetic information session by calling 650-249-9090 or visiting naterasession.com. Clinicians with questions may contact Natera at 650-249-9090 or email support@natera.com. Individuals with positive results may wish to discuss these results with family members to allow them the option to be screened. Comprehensive genetic counseling to discuss the implications of these test results and possible associated reproductive risk is recommended.

Patient-friendly reports



Empower

Positive report

FINAL RESULTS SUMMARY

Positive



A pathogenic variant in the BRCA1 gene was detected. This variant is associated with an INCREASED CANCER RISK.

Next-generation sequencing-based copy number analysis was inconclusive (see below). Redraw for blood sample will be accepted.

FINDINGS: POSITIVE VARIANT(S)

Gene	Associated Disease(s)	Variant	Zygosity	Classification
BRCA1	Hereditary Breast and Ovarian Cancer Syndrome	c.68_69delAG (p.E23Vfs*17)	heterozygous	pathogenic

Interpretation

A heterozygous pathogenic variant, c.68_69delAG (p.E23Vfs*17) in the BRCA1 gene, was detected. This change creates a premature termination codon in the BRCA1 gene and is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are considered to be pathogenic (PMID: 20104584). This pathogenic variant is a known common cause of breast and ovarian cancer in the Ashkenazi Jewish population (PMID: 9042909, 22430266) and has been observed in individuals from other ethnicities (PMID: 8651293, 8571953, 9921907). This variant has also been reported in individuals affected with pancreatic cancer (PMID: 15994883, 22430266, 23658460, 24737347). This variant has been classified as pathogenic by multiple submitters and reviewed by an expert panel in the ClinVar database (Variation ID: 17662).

Please note, due to compromised sample quality of this specimen, next-generation sequencing-based copy number variation (CNV) analysis was uninformative. CNV analysis did not pass our internal quality control metrics, and the presence of large deletions and/or duplications cannot be excluded. Natera will repeat the next-generation sequencing-based CNV analysis at no additional charge if a new sample from the patient is submitted (blood sample is required). The blood sample must be submitted with a new requisition and a copy of this report.

Patient-friendly reports



Empower

Negative with VUS report

VUS is always included as an additional finding

FINAL RESULTS SUMMARY



Negative

No known pathogenic or likely pathogenic variants were detected.

Genes analyzed on this panel

APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM, HOXB13, KIT, MEN1, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PDGFRA, PMS2, PTEN, RAD50, RAD51C, RAD51D, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, TSC1, TSC2, VHL, MSH3, POLE, RPS20, POLD1, NTHL1, AXIN2, BAP1, CTNNA1, GALNT12, GREM1, RNF43

ADDITIONAL FINDINGS: VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS)

Variants of uncertain significance (VUS) are common and the American College of Medical Genetics and Genomics (ACMG) states that a VUS should NOT be used in clinical decision making. A VUS means that a change in the DNA was detected, but there is not enough information to determine whether or not the change increases the risk of cancer. Many VUS represent normal human variation. Medical management should be based on the patient's personal and/or family history.

Gene	Variant	Zygoty	Classification
ATM	c.6736_6755del20insCA (p.C2246_T2252delinsH)	heterozygous	VUS

Interpretation


A heterozygous variant of uncertain significance (VUS) was detected in the ATM gene as tabulated above. This variant has been reported by one submitter in the ClinVar database (Variant ID: 420013, also known as c.641-16421_641-16402delinsTG) and was classified as likely pathogenic. This variant has also been previously reported in a homozygous state in one patient with ataxia-telangiectasia (PMID: 10425038). This variant has not been previously reported in the gnomAD population database. Due to the limited information currently available in public databases and in the medical literature, we have classified this change as a variant of uncertain significance.

Report supplements

Clarifying positive results and next steps



Panorama NIPT Trisomy 21 supplement

Panorama™ Report Supplement:  panorama
Trisomy 21 (Down syndrome)

Your screening test result shows a high risk for Trisomy 21 (Down syndrome). You are receiving this fact sheet because you had a Panorama screening result that showed a 'high risk' for this specific chromosome condition. **This screening result DOES NOT mean your baby has this condition.** The blood test you took is a screening test that looks to see if your baby is at a higher than average chance to have certain chromosome conditions. It does not diagnose or confirm the condition. To know for sure whether or not your baby has this condition, you need to have a diagnostic test such as an amniocentesis or CVS during pregnancy or a blood test after your baby is born. More information on follow-up diagnostic testing is listed below. **Decisions about your pregnancy SHOULD NOT be made based on the screening results alone as your baby may not have this condition.**

What is Down syndrome?
Trisomy 21, also called Down syndrome, is a chromosome condition caused by an extra 21st chromosome. Usually, humans have 46 chromosomes that come in 23 pairs. Children who have Down syndrome have three copies of chromosome 21 instead of two.

What are the common features of Down syndrome?
Children with Down syndrome have intellectual disabilities and specific physical features. They may have heart defects, weak muscle tone, and can be smaller than average. Other health and learning problems can also occur in children with Down syndrome but these problems will vary from child to child. Every child with Down syndrome is unique.

How common is Down syndrome?
About 1 in 600 babies is born with Down syndrome.


Do children with Down syndrome need extra medical care?
Yes, children with Down syndrome will need extra medical care depending on the child's specific health problems.

Do babies with Down syndrome have a normal lifespan?
Most people with Down syndrome live into their 60s and many live even longer. The presence of medical conditions, like heart defects, can affect the lifespan in these children and adults. Miscarriage occurs in about 30% of pregnancies with Down syndrome.

Do babies with Down syndrome have normal IQs?
Most children with Down syndrome have intellectual disabilities that range from mild to moderate. Early intervention has been shown to benefit children born with Down syndrome. Many children with Down syndrome learn to read and write and participate in normal activities.

How does Down syndrome happen?
In most cases, Down syndrome happens by chance. There is nothing you can do before or during pregnancy to cause or prevent Down syndrome.

What is the next step?
Natera's Panorama Test screens the mother's blood to find the baby's DNA and looks for specific chromosome problems. This form of screening is new¹. It is recommended that you talk to a doctor or genetic counselor about more testing to find out if the baby has Down syndrome. Two tests are available in pregnancy to check the baby's chromosomes. One test is chorionic villus sampling (CVS), which can be done at 10 to 12 weeks of pregnancy. Another test is amniocentesis, which can be done as early as 15 weeks of pregnancy. If you do not want more prenatal testing, chromosome testing can be done for the baby after he or she is born.

Panorama™ Report Supplement:  panorama
Trisomy 21 (Down syndrome)

Where can I learn more about Down syndrome?
Your healthcare provider can refer you to a genetics professional in your area. Genetics professionals such as medical geneticists and genetic counselors can discuss conditions like Down syndrome in more detail and answer any questions you may have about your results.

Additional information on Down syndrome can be found online:

- March of Dimes
http://www.marchofdimes.com/baby/birthdefects_chromosomal.html
- National Down Syndrome Society
<http://www.ndss.org>
- National Down Syndrome Society Local Support Group Listings
<http://www.ndss.org/Resources/Local-Support-Group-Listings>
- Genetics Home Reference
<http://ghr.nlm.nih.gov/condition/down-syndrome>

Where can I find a genetic counselor?
You may find a local genetic counselor through the National Society of Genetic Counselors at www.nsgo.org.


1. Nussbaum et al. 2007. Thompson and Thompson Genetics in Medicine (7th Ed.) Oxford Saunders, Philadelphia, PA.
2. The Panorama prenatal screening test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

Report supplements

Clarifying positive results and next steps



Horizon Carrier Screen SMA supplement

 horizon
genetic carrier screen

SPINAL MUSCULAR ATROPHY

Understanding Your Horizon™ Carrier Screen Results

What is Spinal Muscular Atrophy?

Spinal Muscular Atrophy (SMA) is a serious inherited disorder that typically begins in infancy or childhood and causes worsening muscle weakness, decreased ability to breathe, and loss of motor skills. Most children with SMA have one of the early-onset forms with symptoms that begin in infancy. Without treatment, death often occurs before the age of two. Some children have juvenile-onset SMA and develop muscle weakness and other symptoms later in childhood and typically have a normal lifespan. In rare cases symptoms do not begin until early adulthood, are less severe, and do not affect lifespan. Currently there is no cure for SMA, although new medications may be available to lessen or stop the progression of symptoms of SMA, especially when treatment is started early. Clinical trials involving potential new treatments for this condition may be available (see www.clinicaltrials.gov).

What causes Spinal Muscular Atrophy?

SMA is caused by a change, or mutation, in both copies of the SMN2 gene pair. These mutations, which often delete part or all of these genes, cause the genes to work improperly or not work at all. When both copies of the SMN2 gene are missing or do not work correctly, it leads to the symptoms described above.


SMA is inherited in an autosomal recessive manner. This means that, in most cases, both parents must be carriers of a mutation in one copy of SMN2 to have a child with SMA. People who are SMA carriers are usually healthy and do not have symptoms nor do they have SMA themselves. Usually a child inherits two copies of each gene, one copy from the mother and one copy from the father. If the mother and father are both carriers for SMA, there is a 1 in 4, or 25%, chance in each pregnancy for both partners to pass on their SMN2 gene mutations to the child, who would then have SMA. With further testing (not offered through Natera), it is sometimes, but not always, possible to determine whether a given carrier couple is at risk to have a child with a severe, early-onset form of SMA, the juvenile form, or the later-onset form.

Individuals found to carry more than one mutation for SMA should discuss their risk for having an affected child, and any potential risks to their own health, with their health care provider.

What can I do next?

You may wish to speak with a local genetic counselor about your carrier test results. A genetic counselor in your area can be located on the National Society of Genetic Counselors website (www.nsgc.org).

1

 horizon
genetic carrier screen

Your siblings and other relatives are at increased risk to also have this mutation. You are encouraged to inform your family members of your test results as they may wish to consider being tested themselves.

If you are pregnant, your partner can have carrier screening for SMA ordered by a health care professional. Partner screening may include SMN2 testing and possibly Enhanced SMA testing. Enhanced SMA testing can provide information on the chance to still be a carrier even after a normal (negative) SMA carrier screen. Your doctor or a local genetic counselor can help decide which carrier test is best for your partner. If your partner is not found to be a carrier of SMA, your risk of having a child with SMA is greatly reduced.

Couples at risk of having a baby with SMA can opt to have prenatal diagnosis done through chorionic villus sampling or amniocentesis during pregnancy or can choose to have the baby tested after birth for SMA.

If you are not yet pregnant, your partner can have carrier testing for SMA ordered by a health care professional. Partner testing may include SMN2 testing and possibly Enhanced SMA testing. Enhanced SMA testing can provide information on the chance to still be a carrier even after a normal (negative) SMA carrier screen. Your doctor or a local genetic counselor can help decide which carrier test is best for your partner. If your partner is found to be a carrier for SMA, you have several reproductive options to consider:

- Natural pregnancy with or without prenatal diagnostic testing of the fetus or testing the baby after birth for SMA
- Preimplantation genetic diagnosis (PGD) with in vitro fertilization (IVF) to test embryos for SMA
- Adoption or use of a sperm or egg donor who is not a carrier for SMA

What resources are available?

- Families of SMA: <http://uresma.org/ESMACommunity/understandingsma>
- GeneReviews: <https://www.ncbi.nlm.nih.gov/books/NBK1357/>
- Prenatal diagnosis done through CVS: <http://www.marchofdimes.org/chorionic-villus-sampling.aspx>
- Prenatal diagnosis done through amniocentesis: <http://www.marchofdimes.org/amniocentesis.aspx>
- PGD with IVF: <http://www.natera.com/soectrum>

2

Report supplements

Evidence-based cancer risks and guidelines-based patient management recommendations



Empower Hereditary Cancer Test BRCA2 supplement

Cancer Risk Estimates for *BRCA2*

Cancer risk estimates for a positive result are typically based on individuals with a family or personal history of cancer. Your risk may be different if you do not have a personal or family history of cancer.

Female	Cancer type	General Population - Estimated Lifetime Cancer Risk*	Positive Result - Estimated Lifetime Cancer Risk**
♀	Breast	12.80%	Up to 84% risk
	Ovarian	1.3%	Up to 27% risk
	Pancreatic	1.60%	2-7%
	Melanoma	1.80%	Increased

Risk Management and Screening Guidelines for Hereditary Breast and Ovarian Cancer Syndrome *

The following information is a summary of current US guidelines. Please discuss with your healthcare provider as screening recommendations may vary by country and can change often.

Cancer type	Mode of Screening or Risk Reduction	Typical Age to Begin	How often
Female Breast	Breast self-exam	18	Monthly
	Breast exam with clinician	25	Every 6-12 months
	Breast MRI with contrast	25-29 or individualized if family history of breast cancer below age 30	Annually
	Mammogram with consideration of tomosynthesis (3-D Mammogram)	30	Annually
	Risk-reducing medication	Individualized	Discuss with your healthcare provider
	Risk-reducing breast surgery (mastectomy); discuss with your healthcare provider	Individualized; a consideration for those with a personal and/or family history of breast cancer	N/A
Male Breast	Breast self-exam	35	Monthly
	Breast exam with clinician	35	Annually

Report supplements include detailed patient management recommendations based on medical guidelines



Next Steps








Next Steps

Value-add services that go beyond the test to address what's next

Post-test genetic info sessions and provider consultations




Schedule by:

-  Calling Natera Customer Care
-  Visiting the online patient portal
-  Texting SESSION to 484848 (patients only)

Family testing program



Empower testing for first-degree relatives of patients with a positive result is available at no additional charge.

 Visit natera.com/empower for more details.

Spectrum Advantage Program



Empower and Horizon patients can access Spectrum preimplantation genetic testing at discounted rates

Post-test genetic info sessions and provider consultations

Patient and provider access to board-certified genetic experts



Schedule by:



Calling Natera
Customer Care



Visiting the online
patient portal



Texting **SESSION** to
484848 (patient only)


- Appointments available Mon–Fri 6am to 5pm Pacific
- Scheduled online or via phone
- Note summarizing session is sent to health care provider within 48 hours and available on Natera Connect for easy reference

On-Demand Genetic Information Sessions

Same day genetic information sessions available for Horizon and Panorama



Schedule by:

 Calling Natera Customer Care

- Patients can choose between two options:
 - On-Demand: Request same day callback
 - Appointment: Schedule an appointment on a specific day/time
- On-Demand service available Mon–Fri 6am to 5pm Pacific, until capacity met


Horizon Partner Auto-Enroll

Automated workflow for carrier screen partner testing

Patient tests positive

Physician

Approves partner order in NateraConnect*




- ✓ Order automatically generated
- ✓ Select test panel and sign


Partner

Receives order, watches test video

Reviews personalized cost estimate and signs order




- ✓ Receives order by text/email
- ✓ Watches educational video and gets personalized cost



- ✓ Schedules blood draw
- ✓ Signs order

Physician

Accesses real time update on order status



- ✓ Stay informed on Order Status

* Partner information and consent must be provided to complete partner testing

Empower Family Testing Program



Testing for first-degree relatives of patients with a positive result is available at no additional charge



Order must be received within 90 days of original report date



Panel must be the same size or smaller compared to previous relative's test order.




Not available to family members covered by government insurance plans.

Spectrum Advantage Program

Increased access to PGT



For couples screened positive with Horizon, Natera offers Spectrum Advantage \$99 pre-implantation genetic testing*



* Spectrum PGT-M and PGT-A must be performed within one year of Horizon screening results. Promotional price good for one test run. Shipping and batching fees apply. Restrictions apply. Both male and female must have completed a Horizon panel (Horizon 4, 14, 27, 106, 137, or 274). Prior carrier screening identifying positive risk for a disorder voids special pricing.

Spectrum Advantage Program


Increased access to PGT



Horizon™
Advanced carrier screening

Empower™
Hereditary cancer test

For patients who test positive with Empower hereditary cancer testing, Natera offers Spectrum Advantage pre-implantation genetic testing at a significant discount*



*Spectrum PGT-M and PGT-A must be performed within one year of Empower test results. Does not apply for patients with a VUS result. Shipping and batching fees apply. Promotional price good for one test run and not valid if patient chooses to file insurance. Restrictions apply. Prior carrier screening/genetic testing identifying positive risk for a disorder voids special pricing. Patients that have participated in the Empower family testing program are not eligible for Spectrum Advantage.



The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved.